# A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects

> **NCT01205737** · PHASE1 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 186 (actual)

## Conditions studied

- DLBCL

## Interventions

- **BIOLOGICAL:** TL011
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT01205737
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-07
- **Final completion:** 2013-09
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2013-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01205737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01205737, "A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01205737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*